Compare · LUCY vs STAA
LUCY vs STAA
Side-by-side comparison of Innovative Eyewear Inc. (LUCY) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCY and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- STAA is the larger of the two at $1.12B, about 152.1x LUCY ($7.3M).
- Over the past year, LUCY is down 55.4% and STAA is down 15.0% - STAA leads by 40.4 points.
- LUCY has been more active in the news (6 items in the past 4 weeks vs 4 for STAA).
- STAA has more recent analyst coverage (25 ratings vs 0 for LUCY).
- Company
- Innovative Eyewear Inc.
- STAAR Surgical Company
- Price
- $0.81-4.08%
- $21.27-4.45%
- Market cap
- $7.3M
- $1.12B
- 1M return
- -9.84%
- +0.14%
- 1Y return
- -55.42%
- -15.00%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 6
- 4
- Recent ratings
- 0
- 25
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest LUCY
- SEC Form 8-K filed by Innovative Eyewear Inc.
- SEC Form 8-K filed by Innovative Eyewear Inc.
- Innovative Eyewear, Inc. Launches Lucyd Aero
- Innovative Eyewear Reports Record Preliminary Q3 2026 Net Sales, Up 55% Year-Over-Year
- SEC Form DEF 14A filed by Innovative Eyewear Inc.
- SEC Form PRE 14A filed by Innovative Eyewear Inc.
- Innovative Eyewear, Inc. Announces Exclusive Australia and New Zealand Distribution Partnership with Directed Electronics
- Innovative Eyewear, Inc. Announces Q3 Business Update
- Chief Financial Officer Gayle Oswald was granted 32,466 shares and sold $13,491 worth of shares (15,533 units at $0.87), increasing direct ownership by 591% to 19,798 units (SEC Form 4)
- Chief AI & Growth Officer Dabrowski Konrad sold $11,874 worth of shares (13,627 units at $0.87) and was granted 41,800 shares, increasing direct ownership by 220% to 40,977 units (SEC Form 4)
Latest STAA
- STAAR Surgical Names Andrew Pilon as Vice President of Business Development
- Amendment: STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical upgraded by Stifel with a new price target
- STAAR Surgical Board Approves $50 Million Share Repurchase Authorization
- STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction
- STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
- Chief Development Officer Michna Magda exercised 6,599 shares at a strike of $4.36 and covered exercise/tax liability with 3,356 shares, increasing direct ownership by 9% to 41,343 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 5,233 shares and covered exercise/tax liability with 2,662 shares, increasing direct ownership by 7% to 38,910 units (SEC Form 4)
- President and CEO Foust Warren converted options into 10,997 shares and covered exercise/tax liability with 5,595 shares, increasing direct ownership by 11% to 95,816 units (SEC Form 4)
- SEC Form 10-Q filed by STAAR Surgical Company